Subpotent Drug: FDA analysis found product to be subpotent
💊
Prescription Drugs
💊 Drugs • 12,141 recalls
CGMP Deviations: manufactured under the same conditions as those found to be subpotent.
CGMP Deviations: manufactured under the same conditions as those found to be subpotent.
Subpotent Drug: FDA analysis found product to be subpotent
CGMP Deviations: manufactured under the same conditions as those found to be subpotent.
CGMP Deviations: manufactured under the same conditions as those found to be subpotent.
CGMP Deviations: manufactured under the same conditions as those found to be subpotent.
CGMP Deviations: manufactured under the same conditions as those found to be subpotent.
CGMP Deviations: manufactured under the same conditions as those found to be subpotent.
Class I - Dangerous
Subpotent Drug: FDA analysis found product to be subpotent
CGMP Deviations: manufactured under the same conditions as those found to be subpotent.
CGMP Deviations: manufactured under the same conditions as those found to be subpotent.
Class I - Dangerous
Subpotent Drug: FDA analysis found product to be subpotent
Class I - Dangerous
Subpotent Drug: FDA analysis found product to be subpotent
Class I - Dangerous
CGMP deviations; there is a possibility that some bottles in these lots may have the active ingredient above and/or below specification limits.
Class I - Dangerous
CGMP deviations; there is a possibility that some bottles in these lots may have the active ingredient above and/or below specification limits.
Cephalexin for Oral Suspension, USP 250 mg per 5 mL, For Reconstitution, For Oral Use Only, Rx Only, 100 mL bottle when mixed, Teva Pharmaceuticals USA, Inc., North Wales, PA 19454, NDC 0093-4177-73.
Teva Pharmaceuticals USA
Class I - Dangerous
Sub-Potent Drug: Out of specification test results for potency (below specification).
Class I - Dangerous
Labeling: Error on Declared Strength
Class I - Dangerous
Labeling: Label Mix-Up; potential for cartons labeled as Tranexamic Acid Injection, USP to contain vials of Amiodarone HCl Injection, USP and cartons labeled as Amiodarone HCl Injection, USP to contain vials of Tranexamic Acid Injection, USP.
Class I - Dangerous
Labeling: Label Mix-Up; potential for cartons labeled as Tranexamic Acid Injection, USP to contain vials of Amiodarone HCl Injection, USP and cartons labeled as Amiodarone HCl Injection, USP to contain vials of Tranexamic Acid Injection, USP.